Canaccord analyst Austin Moeller lowered the firm’s price target on Bioceres (BIOX) to $6.50 from $7 and keeps a Buy rating on the shares. The firm noted management announced its intent to pivot away from Bioceres’ seed business to focus on trait development and leverage key partnerships to expand its footprint internationally.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue